CA2694466A1 - Immunogenic polypeptides and monoclonal antibodies - Google Patents

Immunogenic polypeptides and monoclonal antibodies Download PDF

Info

Publication number
CA2694466A1
CA2694466A1 CA2694466A CA2694466A CA2694466A1 CA 2694466 A1 CA2694466 A1 CA 2694466A1 CA 2694466 A CA2694466 A CA 2694466A CA 2694466 A CA2694466 A CA 2694466A CA 2694466 A1 CA2694466 A1 CA 2694466A1
Authority
CA
Canada
Prior art keywords
seq
xxxx
produced
nucleic acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2694466A
Other languages
English (en)
French (fr)
Inventor
Roger Brookes
Robert Charlebois
Martina Ochs
Jeremy Yethon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2694466A1 publication Critical patent/CA2694466A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
CA2694466A 2007-07-23 2008-07-23 Immunogenic polypeptides and monoclonal antibodies Abandoned CA2694466A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96172307P 2007-07-23 2007-07-23
US60/961,723 2007-07-23
PCT/CA2008/001353 WO2009012588A1 (en) 2007-07-23 2008-07-23 Immunogenic polypeptides and monoclonal antibodies

Publications (1)

Publication Number Publication Date
CA2694466A1 true CA2694466A1 (en) 2009-01-29

Family

ID=40280955

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2694466A Abandoned CA2694466A1 (en) 2007-07-23 2008-07-23 Immunogenic polypeptides and monoclonal antibodies

Country Status (12)

Country Link
US (1) US8337846B2 (enExample)
EP (1) EP2183366B1 (enExample)
JP (3) JP2010535015A (enExample)
KR (1) KR101595234B1 (enExample)
CN (1) CN101802198B (enExample)
AU (1) AU2008280799B2 (enExample)
BR (1) BRPI0814127A2 (enExample)
CA (1) CA2694466A1 (enExample)
ES (1) ES2397488T3 (enExample)
IL (1) IL203429A0 (enExample)
WO (1) WO2009012588A1 (enExample)
ZA (1) ZA201001260B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
CN102939105B (zh) 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
WO2011075823A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
EP2810078A4 (en) 2012-02-01 2016-02-17 Oklahoma Med Res Found HUMAN STREPTOCOCCUS PNEUMONIAE ANTIBODIES AND APPLICATIONS THEREOF
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CN105754952B (zh) * 2016-02-16 2020-07-10 中国农业科学院兰州兽医研究所 抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
CN112219117B (zh) * 2018-03-20 2024-09-27 赛诺菲巴斯德有限公司 使用内源荧光测定佐剂化蛋白质浓度和吸附百分比的方法
US20240117019A1 (en) * 2021-02-09 2024-04-11 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
CA2123811C (en) * 1991-11-22 2005-07-05 Ali Ibrahim Fattom Type i and type ii surface antigens associated with staphylococcus epidermidis
US6582708B1 (en) * 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
DE69940439D1 (de) 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
KR100802198B1 (ko) * 1998-12-23 2008-02-11 샤이어 바이오켐 인코포레이티드 신규한 스트렙토코커스 항원
EP1165795A2 (en) * 1999-03-26 2002-01-02 Provalis UK Limited Streptococcus pneumoniae antigens
AU2001269833A1 (en) * 2000-06-14 2001-12-24 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
US7074415B2 (en) * 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
WO2001098334A2 (en) * 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP1456231A2 (en) * 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
US6720918B2 (en) * 2002-09-17 2004-04-13 Space Systems/Loral, Inc. Antenna distortion estimation and compensation
EP2333114A1 (en) * 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
MXPA06000264A (es) * 2003-07-10 2006-04-07 Wyeth Corp Expresion recombinante de cisteina proteasa de streptococcus pyogenes y composiciones inmunogenicas de las mismas.
JP5219803B2 (ja) * 2005-05-13 2013-06-26 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド グラム陽性菌の血清耐性因子
JP5509176B2 (ja) * 2011-10-21 2014-06-04 株式会社日立製作所 計算機システムおよび計算機システムにおけるモジュール引き継ぎ方法

Also Published As

Publication number Publication date
JP6204053B2 (ja) 2017-09-27
KR20100053564A (ko) 2010-05-20
AU2008280799B2 (en) 2013-07-11
US8337846B2 (en) 2012-12-25
EP2183366B1 (en) 2012-10-24
ZA201001260B (en) 2010-10-27
JP2010535015A (ja) 2010-11-18
JP2016005482A (ja) 2016-01-14
AU2008280799A1 (en) 2009-01-29
EP2183366A1 (en) 2010-05-12
CN101802198B (zh) 2016-02-17
WO2009012588A1 (en) 2009-01-29
IL203429A0 (en) 2011-07-31
US20100297133A1 (en) 2010-11-25
CN101802198A (zh) 2010-08-11
EP2183366A4 (en) 2010-09-01
JP2013212108A (ja) 2013-10-17
KR101595234B1 (ko) 2016-02-26
ES2397488T3 (es) 2013-03-07
BRPI0814127A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
AU2008280799B2 (en) Immunogenic polypeptides and monoclonal antibodies
AU2009329782B2 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
JP4469026B2 (ja) Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
US8252546B2 (en) Diagnosing pneumococcal pneumonia
JP2004501618A (ja) ストレプトコッカス抗原
KR20070122458A (ko) 표재성 스트렙토코커스 뉴모니아 폴리펩티드
PL197449B1 (pl) Wyizolowane polipeptydy, immunogenne fragmenty tych polipeptydów, wyizolowane polinukleotydy, wektor ekspresyjny, komórka gospodarza zawierająca taki wektor, sposób wytwarzania polipeptydu, sposób ekspresji polinukleotydu, kompozycja szczepionki, przeciwciało immunospecyficzne w stosunku do polipeptydu lub jego immunogennego fragmentu, sposób diagnozowania zakażenia Neisseria meningitidis, zastosowania kompozycji zawierającej polipeptyd lub jego immunogenny fragment, lub polinukleotyd i kompozycja terapeutyczna do leczenia choroby wywołanej przez Neisseria meningitidis
US20040131634A1 (en) Neisseria lactoferrin binding protein
AU2013204613A1 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
CN101977927A (zh) 针对肺炎链球菌保护的肽以及与其有关的组合物、方法和用途
US20130184200A1 (en) Immunogenic Polypeptides and Monoclonal Antibodies
Class et al. Patent application title: Immunogenic Polypeptides and Monoclonal Antibodies Inventors: Martina Ochs (Toronto, CA) Roger Brooks (Toronto, CA) Robert Charlebois (Toronto, CA) Jeremy Yethon (Milton, CA)
AU2016254447A1 (en) Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
HK1243089A1 (en) Immunogenic pcpa polypeptides and uses thereof
EP1939215A1 (en) Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140723